Keryx Biopharma - KERX

domani hanno detto

Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results - Yahoo! Finance

..

..At September 30, 2009, the Company had cash, cash equivalents, interest receivable and investment securities of $41.0 million, as compared to $22.7 million at December 31, 2008. On September 30, 2009, the Company completed a $20.0 million registered direct offering of common stock and warrants, which provided proceeds to the Company of approximately $18.4 million, net of offering costs of approximately $1.6 million which were paid subsequent to September 30, 2009..

..

..Commenting on the quarter, Ron Bentsur, the Company's Chief Executive Officer, remarked, "Keryx has made substantial progress in the third quarter. Following our announcements of an SPA for the Phase 3 trial of perifosine in multiple myeloma, and exciting long-term safety and efficacy data for Zerenex, we solidified our balance sheet with a $20 million registered direct offering." Mr. Bentsur added, "We believe we now have sufficient capital to complete the Phase 3 programs for Perifosine and Zerenex, both of which are nearing commencement"..
 
Zerenex®

Keryx possiede i diritti per USA di sicuro e forse per NordAmerica

in ultima call conference han detto qualcosa dell'accordo fra Keryx e Torii/JT per il mercato Giapponese ..ma non ho ben capito se hanno "solo" ridiscusso i termini economici ..oppure Torii/JT si presa in toto e definitivamente la molecola per quel mercato

e per il resto del mondo ? ..Europa inclusa

Novartis ha registrato in Europa nome e molecola ZERENEX® , ma trattasi

  • ..di proprietà esclusiva per il mrcato Europeo
  • ..o c'é anche qui di mezzo un accordo economico con Keryx ?

:-?

se fosse la seconda che ho scritto :eek:
1257945112zerenex.jpg
 
AEterna Zentaris Partner, Keryx Biopharmaceuticals, Announces Poster Presentation Highlighting Clinical Activity of Perifosine (KRX-0401) at 51st Annual Meeting of the American Society of Hematology - Yahoo! Finance

QUEBEC CITY, Nov. 11 /PRNewswire-FirstCall/ -

AEterna Zentaris Inc. (NASDAQ: AEZS - News; TSX: AEZ - News; the Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX - News), its partner and licensee for perifosine (KRX-0401) in the North American market, will present data from a Phase 1/2 clinical trial of perifosine in combination with bortezomib (+/- dexamethasone), during a poster presentation session at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009. The clinical data to be presented demonstrates the potential safety and efficacy of perifosine in the treatment of patients with relapsed/refractory multiple myeloma.
 
Bingo!

AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma

......Ron Bentsur, Chief Executive Officer of Keryx Biopharmaceuticals, commented, "This Fast Track designation can significantly reduce the FDA review time of a new drug application, and therefore can expedite the time to market for perifosine in multiple myeloma." Mr. Bentsur added, "We believe that the Fast Track designation, together with the SPA and Orphan Drug status previously granted to us by the FDA for perifosine in multiple myeloma, significantly enhances the value proposition of perifosine in this indication. We are eager to begin the Phase 3 trial later this month."......

Grazie Acqua+ :up:
 

Users who are viewing this thread

Back
Alto